NCT04002674View on ClinicalTrials.gov

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Dementia With Lewy Bodies

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

December 30, 2023

Study Completion Date

December 30, 2023

Conditions
Dementia With Lewy Bodies
Interventions
DRUG

Placebo oral capsule

"Thirty (30) patients in arm 1 will receive the matching placebo (sugar pill) one (1) capsule orally (without food) once daily for 6 months (180 days)."

DRUG

Nilotinib Oral Capsule

Thirty (30) patients in arm 2 will receive the 200 mg of Nilotinib one (1) capsule orally (without food) once daily for 6 months (180 days).

Trial Locations (1)

20007

RECRUITING

MedStar Georgetown University Hospital, Washington D.C.

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

Georgetown University

OTHER